Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIM811
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
NIM811 is a non-immunosuppressive cyclosporine analog and a potent dual inhibitor of mitochondrial permeability transition and cyclophilin. Unlike cyclosporine A, the binary complex of NIM811 with cyclophilin cannot bind to calcineurin and therefore does not exhibit immunosuppressive activity[2][7]. It has demonstrated in vitro antiviral activity against hepatitis C virus (HCV), with clinical studies exploring its use for chronic hepatitis C infection[3][5]. Additionally, it is being investigated as a potential treatment for genetic muscular diseases such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM)[2][7].
- Other names
- (Melle-4)cyclosporin9-(N-methyl-L-isoleucine)-cyclosporin A9-(N-methylisoleucine)cyclosporin A
02
Targets
PPIF (Cyclophilin D)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on NIM811.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIM811.